Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(98 intermediate revisions by 8 users not shown)
Line 1: Line 1:
Welcome!
Welcome!


*For assignments, please see the "Author" column below (3rd column from left). If no name is present, volunteer to create content!
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
 
*For assignments, please see the "Author" column below (highlighted blue).
 
*If empty (no name is present), please volunteer to create content for that disease!
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*Note - NEW (No Prior) means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added.
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
 
__TOC__


<br />
<br />
{| class="wikitable" style="margin:auto"
{| class="wikitable sortable" style="margin:auto"
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content</big>
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|-
|-
!Disease (5th Edition)!!Page Type!!Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Correlated Prior Author (4th Edition)
Line 16: Line 25:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
|
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)====
|
|
----<br />
----<br />
Line 22: Line 32:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
|4/8/24
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 48: Line 72:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 55: Line 79:
|
|
|-
|-
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Neutrophilic Leukemia (CNL)
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 62: Line 87:
|
|
|-
|-
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
Line 69: Line 95:
|
|
|-
|-
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING
| || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 76: Line 103:
|
|
|-
|-
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Essential Thrombocythemia (ET)
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 83: Line 111:
|
|
|-
|-
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Primary Myelofibrosis (PMF)
|Primary Myelofibrosis (PMF)
|T. Niroshi Senaratne, UCLA
|T. Niroshi Senaratne, UCLA
Line 90: Line 119:
|
|
|-
|-
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
| || || || ||FQR|| ||
|Juvenile Myelomonocytic Leukemia (JMML)
|Juvenile Myelomonocytic Leukemia (JMML)
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 101: Line 131:
|FQR has emailed SR several times, last 4/20/22
|FQR has emailed SR several times, last 4/20/22
|-
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Thomas Lee, MD, PhD, University of California, Los Angeles
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 108: Line 155:
|
|
|-
|-
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Cutaneous Mastocytosis
|Cutaneous Mastocytosis
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 115: Line 163:
|
|
|-
|-
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
|Systemic Mastocytosis
|Systemic Mastocytosis
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
|Complete
|Complete
|
|
|
|
|-
|-
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
| || || || ||FQR|| ||
|Mast Cell Sarcoma
|Mast Cell Sarcoma
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 129: Line 178:
|
|
|-
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 136: Line 186:
|
|
|-
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING
| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 164: Line 215:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 171: Line 223:
|
|
|-
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 178: Line 247:
|
|
|-
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 185: Line 255:
|
|
|-
|-
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Myelomonocytic Leukemia (CMML)
|Chronic Myelomonocytic Leukemia (CMML)
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 192: Line 263:
|
|
|-
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
| || || || ||FQR|| ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 199: Line 271:
|
|
|-
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 206: Line 279:
|
|
|-
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 215: Line 289:
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
Line 231: Line 306:
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 247: Line 322:
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 263: Line 338:
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 276: Line 351:
|02/24/2021-MS (re-review)
|02/24/2021-MS (re-review)
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Complete
|
|
|
|JH_MS
|JH_MS
Line 295: Line 386:
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|
|4/15/25
|
|
|
|
Line 311: Line 402:
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 327: Line 419:
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|Gordana Raca MD PhD,
|9/8/25
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 343: Line 435:
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|Disease
|Disease
|Eric McGinnis, MD
|Eric McGinnis, MD, Fatma Al-Bulushi (trannee)
|12/20/23
|12/20/23
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 366: Line 458:
|JH_MS
|JH_MS
|
|
|
|emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG
 
Open to new author
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Xinjie Xu, PhD, FACMG
|Complete
|Complete
|
|
|Add WHO reference
|Add WHO reference<br />
|-
|-
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|
|(Xinxiu Xu)(trainee) Malini Sathanoori, Ph.D.
|
|4/15/25
|
|
|
|
Line 398: Line 493:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
Line 430: Line 525:
|JH_MS
|JH_MS
|
|
|
|Prior author: Celeste Eno, PhD
 
Open to new author
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
Line 436: Line 533:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 455: Line 568:
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 471: Line 584:
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 494: Line 607:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myelomonocytic Leukemia
|Acute Myelomonocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 510: Line 623:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Monoblastic and Monocytic Leukemia
|Acute Monoblastic and Monocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 519: Line 632:
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 542: Line 655:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Megakaryoblastic Leukemia (AMKL)
|Acute Megakaryoblastic Leukemia (AMKL)
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 551: Line 664:
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|Disease
|Disease
|Yalda Naeini
|6/11/24
|
|
|Pending
|
|
|
|JH_MS
|
|
|JH_MS
|
|
|
|
Line 586: Line 699:
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 599: Line 713:
|
|
|Check reference format
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Disease
|Malini Sathanoori, Ph.D.
|12/6/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 625: Line 755:
|JH_MS
|JH_MS
|
|
|
|Prior author:
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
Line 634: Line 765:
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 650: Line 781:
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 666: Line 797:
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 717: Line 848:
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|FQR
|FQR
Line 733: Line 864:
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Disease
|Rolando Garcia
|2/7/2025
|
|
|
|Pending
|
|
|
|
|FQR
|FQR
Line 749: Line 880:
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 762: Line 893:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 797: Line 944:
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 813: Line 961:
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 820: Line 968:
|JH_MS
|JH_MS
|
|
|
|emailed 5/1/24
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
Line 829: Line 977:
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|Disease
|Disease
|Daynna Wolff, PhD
|5/9/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 861: Line 1,009:
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|Disease
|(Rabail Aslam, MD)
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 875: Line 1,024:
|Check reference format
|Check reference format
|-
|-
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
|
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)====
|
|
----<br />
----<br />
Line 881: Line 1,031:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
Line 911: Line 1,073:
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|Disease
|Disease
|
|Daynna Wolff
|
|5/3/2025
|
|8/3/2025
|
|Pending
|
|
|GC
|GC
Line 924: Line 1,086:
|
|
|Previously within myeloid section under JH/MS editors
|Previously within myeloid section under JH/MS editors
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
Line 938: Line 1,116:
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|Complete
|5/19/2022<br />
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|Date completed by author: 04/28/2022
|-
|-
Line 954: Line 1,132:
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|Complete
|5/19/2022<br />
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|Date completed by author: 04/28/2022
|-
|-
Line 975: Line 1,153:
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025
|
|Pending
|
|
|GC
|GC
Line 991: Line 1,169:
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,007: Line 1,185:
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|Disease
|Disease
|
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,023: Line 1,201:
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|Disease
|Disease
|
|Mayuri Shende (trainee) and Scott Turner (mentor)<br />
|
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,067: Line 1,245:
|Complete
|Complete
|10/01/2021
|10/01/2021
|Date completed by author: 10/01/2021
|Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply.
|-
|-
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
|
----<br />
----<br />
Line 1,075: Line 1,270:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,106: Line 1,312:
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,165: Line 1,371:
|Sudha Arumugam, MD
|Sudha Arumugam, MD
|Complete
|Complete
|01/24/2022
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|Date completed by author: 01/24/2022
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,186: Line 1,392:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,202: Line 1,408:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,218: Line 1,424:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Disease
|Holli authoring - Complete? Looks like needs more editing of tables
|Holli Drendel
|
|
|
|
|
|?Complete? Looks like tables need more editing.
|
|
|HD
|HD
Line 1,231: Line 1,437:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,250: Line 1,472:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,266: Line 1,488:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,282: Line 1,504:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,298: Line 1,520:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Disease
|Lei Zhang and Michelle Fan (trainee)
|8/8/2024
|
|
|
|Pending
|
|
|
|
|HD
|HD
Line 1,314: Line 1,536:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,330: Line 1,552:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 1,346: Line 1,568:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|Disease
|Disease
|Aiko Otsubo
|6/25/2024
|
|
|
|Pending
|
|
|
|
|HD
|HD
Line 1,362: Line 1,584:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Disease
|Lei Zhang and Michelle Fan (trainee)
|8/8/2024
|
|
|
|Pending
|
|
|
|
|HD
|HD
Line 1,391: Line 1,613:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|RESOLVE 4th edition ALL-Related NON-WHO entities content
Line 1,411: Line 1,649:
|
|
|-
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| || || || || ||Shivani Golem (SG)
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||
| ||
|Monoclonal B-cell Lymphocytosis
|Monoclonal B-cell Lymphocytosis
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|PENDING
|PENDING, 4/30/2024
|
|
|Assigned 12/19/2022 with completion date of 1/19/2023
|Assigned 12/19/2022 with completion date of 1/19/2023
Line 1,424: Line 1,663:


Honey Reddi, PhD, Belay Diagnostics
Honey Reddi, PhD, Belay Diagnostics
| || ||Complete (Shivani, please confirm)|| ||SG|| ||
| || ||Complete|| ||SG|| ||
|Already converted to 5th edition
|Already converted to 5th edition
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
Line 1,431: Line 1,670:
|
|
|-
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| || || || || ||SG|| ||
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee)/Shivani Golem
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia
|Hairy Cell Leukemia
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
|Complete
|Pending WHO 5th e. July 2024
|
|
|
|
|-
|-
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| || || || || ||SG|| ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi
|4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Marginal Zone Lymphoma
|Splenic Marginal Zone Lymphoma
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,445: Line 1,686:
|
|
|-
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| || || || || ||SG|| ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,461: Line 1,703:
|SG
|SG
|
|
|
|Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia Variant
|Hairy Cell Leukemia Variant
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,472: Line 1,714:
|
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|SG
|SG
|
|
|
|Email sent to request to update 2024
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
Line 1,488: Line 1,730:
|
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|SG
|SG
|
|
|
|Email sent to request to update 2024
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Line 1,504: Line 1,746:
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|Disease
|Disease
|Molly Walkenhorst
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,513: Line 1,755:
|
|
|NEW (No Prior)
|NEW (No Prior)
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|Disease
|Disease
|Andrew Ly
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,543: Line 1,801:
|SG
|SG
|
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric Nodal Marginal Zone Lymphoma
|Paediatric Nodal Marginal Zone Lymphoma
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|Complete
|Complete; Need new author to update latest content. Primary author cannot update the page.
|11/11/2020
|11/11/2020
|
|
Line 1,554: Line 1,812:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|Pending
|
|
Line 1,570: Line 1,828:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|Pending
|
|
Line 1,584: Line 1,842:
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|
|
|
|
|
|SG
|SG
|
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric-Type Follicular Lymphoma
|Paediatric-Type Follicular Lymphoma
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|Complete
|Complete; Need new author to update latest content. Primary author  cannot update the page.
|8/16/2020
|8/16/2020
|
|
Line 1,602: Line 1,860:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/
|Pending
|Pending
|
|
Line 1,616: Line 1,874:
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|Disease
|Disease
|Linlin Gao
|
|
|
|9/4/2025 Sent E-mail to remind
|
|
|
|
|
Line 1,648: Line 1,906:
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|Disease
|Disease
|PENDING
|
|
|
|9/4/2025 set E-mail reminder
|
|
|
|
|
Line 1,657: Line 1,915:
|
|
|Mantle Cell Lymphoma
|Mantle Cell Lymphoma
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Pending
|Pending
|
|
Line 1,664: Line 1,922:
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|Disease
|Disease
|Farhan Sami
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,673: Line 1,931:
|
|
|NEW (No Prior)
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|Disease
|Disease
|Farhan Sami
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,689: Line 1,963:
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
Line 1,708: Line 1,983:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
Line 1,715: Line 1,991:
|
|
|-
|-
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||
|ALK-Positive Large B-cell Lymphoma
|ALK-Positive Large B-cell Lymphoma
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|Pending
|
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|-
|-
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||
| || || || ||GC|| ||
|Large B-cell Lymphoma with IRF4 Rearrangement
|Large B-cell Lymphoma with IRF4 Rearrangement
|Afia Hasnain, MBBS, PhD
|Afia Hasnain, MBBS, PhD
|Complete
|Complete
|5/26/2021
|5/26/2021. Emailed 5/7//2025, no reply
|
|
|-
|-
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||
| || || || ||GC|| ||
|Burkitt-Like Lymphoma with 11q Aberration
|Burkitt-Like Lymphoma with 11q Aberration
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Comlete
|Complete
|27/01/2022
|27/01/2022 Emailed 5/7//2025, no reply
|
|
|-
|-
Line 1,743: Line 2,022:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
|3/22/24|| ||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,757: Line 2,037:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,771: Line 2,068:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||
| || || || ||GC|| ||
|Plasmablastic Lymphoma
|Plasmablastic Lymphoma
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 1,778: Line 2,076:
|
|
|-
|-
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|6/28/2025
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| ||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
Line 1,792: Line 2,092:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025
|8/6/2025 Emailed 9/4/2025 to remind
| || ||GC|| ||
|Intravascular Large B-cell Lymphoma
|Intravascular Large B-cell Lymphoma
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
Line 1,813: Line 2,116:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Complete
|Complete
|16/11/2021
|16/11/2021 Emailed 5/6/2025, no reply
|
|
|-
|-
|Burkitt lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
| || || || ||GC|| ||
|Burkitt Lymphoma
|Burkitt Lymphoma
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Complete
|Complete
|28/06/2021
|28/06/2021 Emailed 5/6/2025, no reply
|
|
|-
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,834: Line 2,155:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,841: Line 2,162:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,848: Line 2,169:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others")|| || || || ||GC|| ||
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
|
|
|
|
Line 1,855: Line 2,176:
|
|
|-
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
| || || || ||GC|| ||
| || || || ||GC|| ||
Line 1,864: Line 2,185:
|
|
|-
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,871: Line 2,192:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
|
|
|
|
Line 1,878: Line 2,199:
|
|
|-
|-
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]")|| || || || ||GC|| ||
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
|
|
|
|
Line 1,885: Line 2,206:
|
|
|-
|-
|Classic Hodgkin lymphoma||Disease|| || || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu
|GC|| ||
|5/7/2025
|8/7/2025 Reminder email sent 9/4/2025|| ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
Line 1,893: Line 2,216:
|
|
|-
|-
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,900: Line 2,225:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Cold agglutinin disease
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
|Disease
|Disease
|
|
Line 1,916: Line 2,257:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,923: Line 2,264:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,930: Line 2,271:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 1,938: Line 2,279:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Immunoglobulin-related (AL) amyloidosis||Disease|| || || || || ||SG
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||
| || || || ||SG
| ||
| ||
|Primary Amyloidosis
|Primary Amyloidosis
Line 1,946: Line 2,288:
|
|
|-
|-
|Monoclonal immunoglobulin deposition disease||Disease|| || || || || ||SG
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||
| || || || ||SG
| ||
| ||
|Light Chain and Heavy Chain Deposition Disease
|Light Chain and Heavy Chain Deposition Disease
Line 1,954: Line 2,297:
|
|
|-
|-
|Mu heavy chain disease||Disease|| || || || || ||SG
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 1,962: Line 2,305:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Gamma heavy chain disease||Disease|| || || || || ||SG
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||
| || || || ||SG
| ||
| ||
|Gamma Heavy Chain Disease
|Gamma Heavy Chain Disease
Line 1,970: Line 2,314:
|
|
|-
|-
|Alpha heavy chain disease||Disease|| || || || || ||SG
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 1,978: Line 2,322:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasmacytoma||Disease|| || || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||
| || || ||
|SG
|SG
| ||
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior)
|NEW (No Prior)
Line 1,987: Line 2,332:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasma cell myeloma / multiple myeloma||Disease|| || || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG
!Disease (5th Edition)
| ||
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo and Zhenya Tang
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
|Pending|| ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
Line 1,995: Line 2,359:
|
|
|-
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
| ||9/4/2025 E-mail sent to Dr. Senaratne
| ||
|SG
|SG
| ||
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
Line 2,004: Line 2,370:
|
|
|-
|-
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|Disease (5th Edition)
|Page Type
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
|Date Assigned to Author (5th Edition)
|Target Completion Date (5th Edition)
|Content Status (5th Edition) (Pending or Complete)
|Date Completed by Author (5th Edition)
|Associate Editor
|Date of Last Editor Review (5th Edition)
|Notes (5th Edition)
|Correlated Prior Disease Name (4th Edition)
|Correlated Prior Author (4th Edition)
|Prior Content Status (4th Edition) (Pending or Complete)
|Prior Date of Last Editor Review (4th Edition)
|Prior Notes (4th Edition)
|-
|
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
|
----<br />
----<br />
Line 2,010: Line 2,393:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,030: Line 2,425:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
|3/25/2024
| || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,037: Line 2,434:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,044: Line 2,441:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,051: Line 2,448:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
|Disease
|Disease
|Fei Yang, MD
|
|
|
|
|Pending
|
|
|
|SK
|
|HD
|
|
|
|
Line 2,067: Line 2,464:
|
|
|-
|-
|T-prolymphocytic leukaemia
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Disease
|Parastou Tizro, MD (trainee); Celeste Eno, PhD
|3/17/2024
|
|
|
|Complete
|
|6/24/2024
|
|
|SK
|SK
|
|7/1/2024
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 2,083: Line 2,480:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|T-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); Michelle Don, MD, MS
|3/17/2024 (trainee name added on 9/9/24 by JH)
|6/30/24
|Pending
| ||SK|| ||
|T-cell Large Granular Lymphocytic Leukemia
|T-cell Large Granular Lymphocytic Leukemia
|Michelle Don, MD, MS
|Michelle Don, MD, MS
Line 2,090: Line 2,507:
|
|
|-
|-
|NK-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
Michelle Don, MD, MS
|3/17/2024
|6/30/24
|Pending
| ||SK|| ||
|Chronic Lymphoproliferative Disorder of NK Cells
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Michelle Don, MD
Line 2,097: Line 2,519:
|
|
|-
|-
|Adult T-cell leukaemia/lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
| || || || ||SK|| ||
|Adult T-cell Leukemia/Lymphoma
|Adult T-cell Leukemia/Lymphoma
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
Line 2,104: Line 2,527:
|
|
|-
|-
|Sezary syndrome||Disease|| || || || || ||SK|| ||
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
| || || ||SK|| ||
|Sézary Syndrome
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,111: Line 2,536:
|
|
|-
|-
|Aggressive NK-cell leukaemia||Disease|| || || || || ||SK|| ||
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|Pending
| ||SK|| ||
|Aggressive NK-cell Leukemia
|Aggressive NK-cell Leukemia
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
Line 2,118: Line 2,546:
|
|
|-
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
|
|3/19/2024
|
| ||Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
|
 
|
Andrew Siref, MD
|
|4/12/2024
|
| ||Pending
|
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mycosis fungoides||Disease|| || || || || ||SK|| ||
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|
|3/22/2024
| || || ||SK|| ||
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Jane Scribner, MD and Daynna J. Wolff, PhD
|
|Pending
|
|
|
|
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|
|7/1/2024
|
|8/31/224
|
|Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); Shashirekha Shetty, PhD
|
|7/1/2024||8/31/2024
|Pending
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|
|Pending
|
|
|
|
|-
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|
|3/19/2024
|
| ||Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
|
|6/30/2024
|
| ||Pending
|
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
 
Andrew Siref, MD
|4/12/2024|| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
| || || || ||SK|| ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
Andrew Siref, MD
|3/20/2024
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|Complete
|1/21/2021
|
|
|-
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
|
Andrew Siref, MD
|3/20/2024
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|
|Pending
|
|
|
|
|-
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
|
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
|Complete
|9/26/2022
|
|
|-
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
Michelle Don, MD, MS
|3/19/2024
|6/30/24
|Complete
|5/13/24||SK||10/18/24||
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Complete
|1/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
Sumire Kitahara, MD
|6/6/24|| ||Pending
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Miguel Gonzalez Mancera, MD
Sumire Kitahara, MD
Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
Sumire Kitahara, MD
|6/6/24|| ||Pending
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|-
|Enteropathy-associated T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|
|4/1/2024
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
| ||Pending|| ||SK|| ||
|
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center
|Pending
|
|
|
|
|-
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|
| ||Pending|| ||SK|| ||prior authors not available
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Angioimmunoblastic T-cell Lymphoma
|
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Pending
|
|
|
|
|-
|-
|Intestinal T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|
| ||Pending|| ||SK|| ||
|Derick Okwan MD, PhD (Stanford Medicine, CA)   Sumire Kitahara MD (Cedars-Sinai, CA)
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Hepatosplenic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
|
| || || || ||SK|| ||
|*Michelle Don, MD, MS
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|Pending
|
|
|
|
|-
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|
|6/25/2023
|
| || || ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
|
|NEW (No Prior)
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc, Teodora Popa (resident)
|
|3/19/2024
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center
| ||Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
| || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
| || || ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Complete
|11/21/2021
|
|
|-
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| || || || || ||SK|| ||
|
|
|* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)====
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
----<br />
|
|
|
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|Disease
|
|
|
|
Line 2,278: Line 2,893:
|
|
|
|
|-
|GC
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|Follicular Dendritic Cell Sarcoma
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|?Pending
|
|
|
|
|-
|-
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
|Disease
|
|
|
|
Line 2,292: Line 2,909:
|
|
|
|
|-
|GC
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
|Disease
|
|
|
|
Line 2,306: Line 2,925:
|
|
|
|
|-
|GC
|Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| ||
|
|*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
|Disease
|
|
----<br />
|
|
----<br />
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
|Disease
|
|
|
|
Line 2,329: Line 2,973:
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Follicular dendritic cell sarcoma
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
|Disease
|Disease
|
|
Line 2,342: Line 2,992:
|
|
|
|
|
|NEW (No Prior)
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|EBV-positive inflammatory follicular dendritic cell sarcoma
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
|Disease
|Disease
|
|
Line 2,358: Line 3,008:
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|
|
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)====
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Fibroblastic reticular cell tumour
|Disease
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|GC
----<br />
|
|
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Intranodal palisaded myofibroblastoma
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|Disease
|N/A||N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|GC
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|
|
|-
|-
|Littoral cell angioma
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|Disease
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|GC
|N/A
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|
|-
|-
|Splenic hamartoma
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A
|Disease
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|GC
|
|
|
|
|
|
|
|-
|-
|Sclerosing angiomatoid nodular transformation (SANT) of spleen
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
|Disease
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|GC
|
|
|
|
|
|
|
|-
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Bloom syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|RASopathies||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|}
|}
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"